Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs

Risultati finali

D1.1 Report on training program oncology (M12)

D1.2 Report on training program business aspects (M12)

Pubblicazioni

Spores of <i>Clostridium</i> engineered for clinical efficacy and safety cause regression and cure of tumors <i>in vivo</i>

Autori: John T. Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, Nigel P. Minton
Pubblicato in: Oncotarget, Numero 5/7, 2014, ISSN 1949-2553
Editore: Impact Journals
DOI: 10.18632/oncotarget.1761

The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy

Autori: Aleksandra M. Kubiak, Nigel P. Minton
Pubblicato in: Research in Microbiology, Numero 166/4, 2015, Pagina/e 244-254, ISSN 0923-2508
Editore: Elsevier BV
DOI: 10.1016/j.resmic.2014.12.006

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

Autori: Alexandra Mowday, Christopher Guise, David Ackerley, Nigel Minton, Philippe Lambin, Ludwig Dubois, Jan Theys, Jeff Smaill, Adam Patterson
Pubblicato in: Cancers, Numero 8/7, 2016, Pagina/e 63, ISSN 2072-6694
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers8070063

Risultati finali

Pubblicazioni

Condividi questa pagina

Scarica